Compare FFIC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | EOLS |
|---|---|---|
| Founded | 1929 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.3M | 444.0M |
| IPO Year | 1995 | 2018 |
| Metric | FFIC | EOLS |
|---|---|---|
| Price | $16.97 | $6.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.80 |
| AVG Volume (30 Days) | 255.7K | ★ 1.8M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $143,853,000.00 | ★ $285,823,000.00 |
| Revenue This Year | $113.60 | $14.36 |
| Revenue Next Year | $7.42 | $23.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $10.65 | $5.71 |
| 52 Week High | $17.94 | $17.12 |
| Indicator | FFIC | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 74.86 | 49.55 |
| Support Level | $16.11 | $6.36 |
| Resistance Level | $16.63 | $7.15 |
| Average True Range (ATR) | 0.46 | 0.31 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 95.77 | 36.69 |
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.